Joleen M. Hubbard, MD

New studies and treatment options prove to be effective in treating metastatic CRC, notes Joleen Hubbard, MD.

The expert panel offers closing thoughts on MRD assessment and how ctDNA has been incorporated into clinical practice in the treatment of colorectal cancer.

Specialists on colorectal cancer discuss the effect of MRD on monitoring strategies and adjuvant therapy decisions for patients with colorectal cancer.

An overview colorectal cancer clinical trials studying early intervention based on MRD positivity.

Aparna Parikh, MD, MS, talks about the MD Anderson INTERCEPT program, which is studying the relationship between ctDNA and recurrence in colorectal cancer.

Daniel H. Ahn, DO, discusses the CIRCULATE-Japan trial, which is studying how ctDNA can be used to guide adjuvant therapy in colorectal cancer.

The panel compares cfDNA with ctDNA for assessing MRD, and outlines when ctDNA testing is ordered and how it’s collected.

Joleen Hubbard, MD, compares CEA with ctDNA for monitoring patients with colorectal cancer.

Medical oncologists who specialize in gastrointestinal cancers offer clinical insights on monitoring patients following treatment with adjuvant chemotherapy.

A comprehensive discussion on treatment decision-making for patients with colorectal cancer following the IDEA collaboration analysis.

The expert panel discusses how MRD positivity affects treatment decisions for patients with colorectal cancer.

Experts on colorectal cancer present a patient case, offer their initial impressions, and discuss disease staging.

Points made in commentaries on “Colorectal Cancer: How Emerging Molecular Understanding Affects Treatment Decisions” are addressed by authors Hubbard and Grothey.

In this review we discuss the current treatment options in metastatic colon cancer, with a special focus on biologic agents and how molecular understanding guides treatment decisions.